Media coverage
1
Media coverage
Title UMIP seeks co-development partner for TSG-6 bone disease candidate Degree of recognition National Media name/outlet Pharma Times Media type Web Country/Territory United Kingdom Date 7/09/10 Description The University of Manchester in the UK is looking for a commercial partner or partners to co-develop a novel protein-based treatment that “could be of major benefit” in bone diseases such as osteoporosis.
The call comes from the university’s intellectual property commercialisation company, UMIP, which has a 12-month licence under an exclusive option from the University of Oxford to conduct further research with TSG-6, a human protein produced by the body at sites of inflammation, and to take the technology forward into global markets.Producer/Author Peter Mansell URL www.pharmatimes.com/news/umip_seeks_co-development_partner_for_tsg-6_bone_disease_candidate_982489 Persons Anthony Day, Caroline Milner